Natural products: A hope for glioblastoma patients

Raghupathy Vengoji, Muzafar A Macha, Surinder Kumar Batra, Nicole A Shonka

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT.

Original languageEnglish (US)
Pages (from-to)22199-22224
Number of pages26
JournalOncotarget
Volume9
Issue number31
DOIs
StatePublished - Apr 24 2018

Fingerprint

temozolomide
Glioblastoma
Biological Products
Neoplastic Stem Cells
Blood-Brain Barrier
Pharmaceutical Preparations
Therapeutics
Survival
Poisons
Adjuvant Chemotherapy
Permeability
Cell Death
Radiotherapy
Clinical Trials
Drug Therapy
Cell Line
Research
Neoplasms

Keywords

  • Blood brain barrier and chemotherapeutic drugs
  • Glioblastoma
  • Temozolomide

ASJC Scopus subject areas

  • Oncology

Cite this

Natural products : A hope for glioblastoma patients. / Vengoji, Raghupathy; Macha, Muzafar A; Batra, Surinder Kumar; Shonka, Nicole A.

In: Oncotarget, Vol. 9, No. 31, 24.04.2018, p. 22199-22224.

Research output: Contribution to journalReview article

Vengoji, Raghupathy ; Macha, Muzafar A ; Batra, Surinder Kumar ; Shonka, Nicole A. / Natural products : A hope for glioblastoma patients. In: Oncotarget. 2018 ; Vol. 9, No. 31. pp. 22199-22224.
@article{55b4be8eafd845a09d92dd047e349e00,
title = "Natural products: A hope for glioblastoma patients",
abstract = "Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT.",
keywords = "Blood brain barrier and chemotherapeutic drugs, Glioblastoma, Temozolomide",
author = "Raghupathy Vengoji and Macha, {Muzafar A} and Batra, {Surinder Kumar} and Shonka, {Nicole A}",
year = "2018",
month = "4",
day = "24",
doi = "10.18632/oncotarget.25175",
language = "English (US)",
volume = "9",
pages = "22199--22224",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

TY - JOUR

T1 - Natural products

T2 - A hope for glioblastoma patients

AU - Vengoji, Raghupathy

AU - Macha, Muzafar A

AU - Batra, Surinder Kumar

AU - Shonka, Nicole A

PY - 2018/4/24

Y1 - 2018/4/24

N2 - Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT.

AB - Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT.

KW - Blood brain barrier and chemotherapeutic drugs

KW - Glioblastoma

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85045958452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045958452&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25175

DO - 10.18632/oncotarget.25175

M3 - Review article

C2 - 29774132

AN - SCOPUS:85045958452

VL - 9

SP - 22199

EP - 22224

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -